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Abstract
Gorlin syndrome (GS) is an autosomal dominant disorder that predisposes affected individ-
uals to developmental defects and tumorigenesis, and caused mainly by heterozygous
germline PTCH1mutations. Despite exhaustive analysis, PTCH1mutations are often
unidentifiable in some patients; the failure to detect mutations is presumably because of
mutations occurred in other causative genes or outside of analyzed regions of PTCH1, or
copy number alterations (CNAs). In this study, we subjected a cohort of GS-affected individ-
uals from six unrelated families to next-generation sequencing (NGS) analysis for the com-
bined screening of causative alterations in Hedgehog signaling pathway-related genes.
Specific single nucleotide variations (SNVs) of PTCH1 causing inferred amino acid changes
were identified in four families (seven affected individuals), whereas CNAs within or around
PTCH1 were found in two families in whom possible causative SNVs were not detected.
Through a targeted resequencing of all coding exons, as well as simultaneous evaluation of
copy number status using the alignment map files obtained via NGS, we found that GS phe-
notypes could be explained by PTCH1mutations or deletions in all affected patients.
Because it is advisable to evaluate CNAs of candidate causative genes in point mutation-
negative cases, NGS methodology appears to be useful for improving molecular diagnosis
through the simultaneous detection of both SNVs and CNAs in the targeted genes/regions.
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Introduction
Nevoid basal cell carcinoma syndrome (NBCCS; OMIM 109400), also known as Gorlin syn-
drome or basal cell nevus syndrome, is an autosomal dominant disorder that predisposes
affected individuals to developmental defects, including bifid ribs and palmar or plantar pits, as
well as tumorigenesis, including the development of basal cell carcinoma, medulloblastoma, or
keratocystic odontogenic tumors (formerly known as odontogenic keratocysts) [1–3]. Hetero-
zygous germline PTCH1mutations have been found in patients with Gorlin syndrome, and the
spectrum of associated features is thought to arise from PTCH1malfunction [4, 5].
Diverse PTCH1mutations have been identified in Japanese Gorlin syndrome patients [6].
Although numerous germline PTCH1mutations have been reported, no clusters of mutations
have been identified [6, 7]. Despite exhaustive analysis, PTCH1mutations are often unidentifi-
able in some patients [6]; for example, Sanger sequencing of PTCH1 exons 2–23, encompassing
the entire coding region, detected mutations in approximately 40%–70% of individuals with a
typical clinical presentation of Gorlin syndrome [8, 9]. This failure to detect mutations is pre-
sumably because of copy number alterations (CNAs), including gross deletions, within or
around the exons of PTCH1, or mutations of PTCH1 outside the analyzed regions such as
those within introns or regulatory elements. In addition, mutations in rare causative genes
other than PTCH1, such as PTCH2 [10, 11] and SUFU [12], have also been detected in individ-
uals suffering from Gorlin syndrome.
Because mutations, or single nucleotide variations (SNVs), as well as CNAs of PTCH1 and
other genes related to the Hedgehog signaling pathway-related genes with numerous exons can
be responsible for Gorlin syndrome, we conducted hybridization and polymerase chain reac-
tion (PCR)-based next generation sequencing (NGS) analyses in a cohort of Gorlin syndrome-
affected individuals from six unrelated families [13, 14] for a combined screening of causative
alterations in candidate genes.
Materials and Methods
Patients and DNA samples
We investigated 15 clinically evaluated Japanese individuals from six pedigrees, including 10
patients with Gorlin syndrome and five unaffected family members (Fig 1). Our group previ-
ously reported the clinicopathologic manifestations of all patients [13, 14], and this informa-
tion is included in Table 1 with the corresponding patient identification codes.
Peripheral blood samples for study were collected after obtaining informed consent from all
participants or their legal guardians, and genomic DNA was extracted using Wizard1 Geno-
mic DNA Purification Kits (Promega, Madison, WI). The study was approved by the ethical
committees of Tokyo Medical and Dental University and Tokushima University. For those
agreeing to participate in this study, written consent was obtained from patients 20 years of age
or older, and from the parent of minor children.
Design of custom targeted exome for NGS
A custom HaloPlex panel (Agilent Technologies, Santa Clara, CA) was designed using Agilent’s
SureDesign tool (www.agilent.com/genomics/suredesign) to capture all exons with 25 bp of the
flanking intronic sequences for eight genes in the Hedgehog signaling pathway: PTCH1,
PTCH2, SHH, SUFU, SMO, GLI, GLI2, and GLI3. The entire custom design comprised 119 tar-
gets with a total size of 42.893 Kb, 3 283 total amplicons, and a final probe design size of 80.612
Kb, with a total theoretical coverage of 99.98% for the targeted regions.
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Sequence capture and NGS
Sequence capture was performed using the HaloPlex Target Enrichment System for Ion Tor-
rent sequencing according to the manufacturer’s instructions (Protocol Version D, Agilent
Technologies). Pooled samples for multiplex sequencing were sequenced using the Ion Per-
sonal Genome Machine System (Thermo Fisher Scientific, Waltham, MA) with 318 chips
(Thermo Fisher Scientific).
SNV analysis and validation
Data were analyzed using Torrent Suite Software v4.2.1 (Thermo Fisher Scientific) and Ion
Reporter Software v4.6 (Thermo Fisher Scientific). The flow chart used to select candidate
genes is shown in Fig 2. Annotated variants were selected according to the criterion that the
causal variants should be segregated in patients with Gorlin syndrome-affected family mem-
bers. Candidates for pathogenic variants within the PTCH1 were confirmed by Sanger sequenc-
ing. The pathogenicity of missense variants was assessed using tools for prediction of possible
impact of an amino acid substitution on the structure and function of a human protein, such as
Sorting Intolerant From Tolerant (SIFT) v5.1.1 (http://sift.bii.a-star.edu.sg/), PolyPhen-2
Fig 1. Family trees of the analyzed families affected by Gorlin syndrome. The shaded circles and squares represent affected individuals. Arrows with “P”
represent the probands in each family.
doi:10.1371/journal.pone.0140480.g001
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v2.2.2r398 (http://genetics.bwh.harvard.edu/pph2/index.shtml), MutationTaster (http://www.
mutationtaster.org/index.html). SIFT examines the degree of conservation for amino
acid residues across species, and calculated probabilities are used to partition ‘tolerated’ (nor-
malized probability>0.05) from ‘damaging’ (normalized probability0.05) substitutions for
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prediction of a phenotypic effect. PolyPhen-2 finds change in protein structure and function,
and provides both a qualitative prediction (one of 'probably damaging', 'possibly damaging',
'benign' or 'unknown') and a score. MutationTaster checks evolutionary conservation, change
in protein structure and function, and additionally effects on splicing or mRNA expression,
and predicts the disease potential: ‘disease causing’, which is probably deleterious, ‘disease
causing automatic’, which is known to be deleterious, ‘polymorphism’, which is probably
harmless, and ‘polymorphism automatic’, which is known to be harmless. Identified SNVs was
also evaluated by comparing with known alterations reported in mutation databases, such as
the Human Gene Mutation Database (HGMD professional 2015.2, http://www.hgmd.cf.ac.uk/
ac/index.php), and ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/).
CNA analysis and validation
The coverage of every target region in each sample was normalized and compared to the aver-
age normalized data from all samples from unaffected family members analyzed in the same
run to determine the relative coverage ratio [15]. Deletions and duplications were suspected to
be present within a genomic interval if this ratio fell below 0.7 or rose above 1.3, respectively.
CNA validation and detailed mapping of altered regions were performed using an Affymetrix
Fig 2. Flow chart indicating the validation process for variants. After four validation steps, nine genetic variants were selected, as shown in Table 2.
doi:10.1371/journal.pone.0140480.g002
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CytoScan HD chromosome microarray platform (Affymetrix, Santa Clara, CA), which pro-
vides 906 600 polymorphic (SNP) and 946 000 non-polymorphic (CNA) markers, according to
the manufacturer’s recommendations. The raw data were processed using Chromosome Anal-
ysis Suite software (ChAS, Affymetrix), and the output data were interpreted with the UCSC
Genome Browser (http://genome.ucsc.edu; GRCh37/hg19 assembly) [16].
Results
In the NGS analysis, which applied our customized Hedgehog pathway-related gene panel to
our cohort of Gorlin syndrome patients and their unaffected family members, a mean coverage
of 282X was obtained per sample and target region. We observed an average of 92.48% of bases
at>1X coverage, 81.68% of bases at>20X coverage, and 64.62% of bases at>100X coverage.
Specific SNVs causing inferred amino acid changes in PTCH1, PTCH2, and GLI2 were found
in four, one, and one families (seven, one, and one affected individuals), respectively, whereas
CNAs within or around PTCH1 were found in two families in which no possible causative
SNVs were detected (Table 2).
Causative genetic alterations identified in each family
Family A. In family A, we identified three mutations in PTCH1 that had been inferred to
cause amino acid changes (Table 2). Among these, the p.Q501R and p.A741V changes in
PTCH1 were predicted to be functionally pathogenic in silico, but have not been reported in
either HGMD or ClinVar. Because p.A741V is listed in the Human Genetic Variation Database
(HGVD, http://www.genome.med.kyoto-u.ac.jp/SnpDB/index.html) at a low frequency (allele
frequency = 0.004) and in dbSNP (http://www.ncbi.nlm.nih.gov/SNP/, rs2227971), we consid-
ered it a non-causative mutation with respect to Gorlin syndrome. In addition, p.Q501R muta-
tion occurred right next to the 4th transmembrane domain (p.502–522). In HGMD, 26 and 2
of 53 missense mutations reported as disease-causing mutations locate within and right next to
any of twelve transmembrane domains of PTCH1, respectively. Since only 251 and 24 of 1447
amino acids locate within or right next to transmembrane domains, transmembrane domains
of the PTCH1 protein seem to be hotspots for missense mutations contributing to functional
defects. Therefore, we concluded that p.Q501R was a novel missense mutation causative for
Gorlin syndrome in family A.
Family B. In family B, we identified a nonsense mutation in PTCH1 (p.Y873). As this
mutation was previously reported to be causative for NBCCS by Boutet et al. [17], we con-
cluded that this alteration was responsible for Gorlin syndrome in family B.
Family C. In family C, we identified missense mutations in PTCH1 and PTCH2 (Table 2).
The p.R175L mutation in PTCH2 was predicted to be “Tolerated” by SIFT, and both p.R175L
and p.R74H mutations in PTCH2 were observed in the HGVD at low frequencies (allele fre-
quency = 0.006 for both variations), suggesting those alterations to be rare benign variants. As
the p.S1132P mutation of PTCH1 was reported to be causative for NBCCS [18], we concluded
that this alteration was responsible for Gorlin syndrome in family C.
Family D. In family D, we identified a possibly deleterious frameshift mutation in PTCH1
(p.I531Gfs92) resulting in a truncated protein lacking 8 of 12 transmembrane domains that
had not been reported in HGMD or ClinVar. On the other hand, the p.A636P mutation in
GLI2 was predicted as “Tolerated” and a “Polymorphism” by SIFT and MutationTaster, respec-
tively. Accordingly, we concluded that p.I531Gfs92 was a novel PTCH1mutation causative of
Gorlin syndrome in family D.
Families E and F. In families E and F, we were unable to identify any causative SNVs
within the target gene coding regions, but rather found deletions within the PTCH1 gene
Genetic Alterations in Gorlin Syndrome
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(Fig 3). A deletion from exon 22 to the 3'-UTR of PTCH1 was observed in family E (Fig 3A),
whereas all exons of PTCH1 were deleted in family F (Fig 3B). These deletions were confirmed
using an array-based copy number analysis (Fig 4). The size of the deletion in family E, as
determined by an array-based method, was approximately 3.8 kb (chr9:98,207,091–98,210,
940) within PTCH1 (from exon 23 to the part of 3’-UTR). As informative probes were not
Fig 3. Graphical representations of DNA copy number alterations across target regions (1p33-p34, 2q14, 7p13, 7q32.3, 7q36, 9q22.3, 10q24.32, and
12q13.2-q13.3), studied via targeted NGS-based exome analysis. (a) The copy number loss shows a region from exon 22 to the 3'-UTR of PTCH1 in a
Gorlin syndrome patient (right panel; individual No. 11, Family E), but not in an unaffected family member (left panel; individual No. 12, Family E). (b) The
copy number loss shows a sequencing region of 9q22.3 in a Gorlin syndrome patient (left panel; individual No. 13, Family F), but not in an unaffected family
member (right panel; individual No. 15, Family F).
doi:10.1371/journal.pone.0140480.g003
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arranged around exons 21 and 22 on the Affymetrix CytoScan HD array platform, it is possible
that the deleted region was underestimated by array-based methods relative to the NGS-based
method. In family F, a relatively large deletion (approximately 1.7 Mb) (chr9:97,579,146–
99,280,739) containing several genes from C9orf3 to CDC14B, including full-length PTCH1,
was detected. These alterations have not been previously reported in HGMD or ClinVar,
indicating them to be novel deletions causative of Gorlin syndrome. The array-based karyotype
results of patients with Gorlin syndrome in families E and F were arr[hg19] 9q22.32(98,
207,091–98,210,940)×1 and arr[hg19] 9q22.32(97,579,146–99,280,739)×1, respectively.
Collectively, the Gorlin syndrome phenotypes were consistent with heterozygous PTCH1
defects caused by various types of mutations or deletions in all investigated families with this
disease.
Discussion
Numerous germline PTCH1mutations, including nonsense, missense, frameshift, and splicing
mutations as well as gross insertions and deletions, have been reported in Gorlin syndrome
patients. Miyashita et al. (http://www.med.kitasato-u.ac.jp/*molgen/sub10.html) genotyped a
panel of Gorlin syndrome patients, finding PTCH1mutations within various percentages of
the patient group: 52.4% were frameshift, 14.3% were nonsense, 11.1% were splicing, and 9.5%
were missense mutations. Despite exhaustive analysis, PTCH1mutations could not be identi-
fied in some patients. This failure to detect mutations was presumably due to large deletions or
the existence of mutations outside of the regions analyzed or in genes other than PTCH1 [6].
Although mutations in PTCH2 and SUFU had been previously implicated in Gorlin syndrome,
none of the prior studies that comprehensively analyzed the Hedgehog signaling pathway-
related genes identified causative genes other than those three genes.
Fig 4. Image of deleted region detected by an array-basedmethod using an Affymetrix CytoScan HD chromosomemicroarray platform. Left panel:
The deletion size was approximately 3.8 kb within the PTCH1 (from exon 23 to part of the 3’-UTR) in family E (upper and lower lanes are individual No. 10 and
No. 12, respectively). Right panel: A relatively large deletion (approximately 1.7-Mb) containing genes from C9orf3 to CDC14B, including full-length PTCH1,
was detected in family F (upper and lower lanes are individual No. 13 and No. 14, respectively).
doi:10.1371/journal.pone.0140480.g004
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In this study, we used NGS to simultaneously screen all exons of 8 Hedgehog signaling path-
way genes in 15 individuals from 6 families, including Gorlin syndrome patients and their
unaffected family members. Through targeted resequencing of all coding exons with flanking
exon-intron junctions, as well as simultaneous evaluation of the copy number status using
alignment map files obtained via NGS, we found that Gorlin syndrome phenotypes could be
explained by PTCH1mutations or deletions in all affected patients. The p.Y873 and p.S1132P
mutations of PTCH1 were previously reported to be causative for NBCCS [17, 18]. Another
missense mutation, a small deletion, and two gross deletions were newly identified alterations
possibly responsible for Gorlin syndrome in the affected families. Although the p.P1318L
PTCH1mutation was previously reported by our group [14], we concluded this mutation not
to be causative because it was predicted to be functionally “tolerated” by SIFT and have been
reported in HGVD as a rare variation. Those results suggest that an NGS-based approach to
the simultaneous detection of candidate for causative alterations in putative target genes with
in silico annotation could effectively identify genetic alterations responsible for Gorlin syn-
drome. Possibly disease-causing alteration was detected in all cases tested in this study. How-
ever, if mutations existed outside of regions targeted for NGS analysis, they would be missed
through this approach. Further examinations using larger cohorts containing both familial and
sporadic cases will be needed to verify the validity of this approach.
Despite reports of numerous germline PTCH1mutations in patients with Gorlin syndrome,
no clustering of mutations has been identified [7]. Previous studies revealed a lack of geno-
type–phenotype correlations between mutations in PTCH1 and the major clinical features of
Gorlin syndrome [8, 19]. On the other hand, large deletions containing the PTCH1might
cause distinguishing symptoms such as mental retardation [20, 21] because of the deletion of
other genes included in the regions around PTCH1. In our study, the 1.7-Mb gene deletion
detected in patient 13 from family F, who exhibited mental retardation, included PTCH1 and
seven other Refseq genes: C9orf3 (NM_032823), FANCC (NM_001243743), ERCC6L2
(NM_001010895),HSD17B3 (NM_000197), SLC35D2 (NM_007001), HABP4 (NM_014282),
and CDC14B (NM_003671). Notably, among these, hyaluronan binding protein 4 (HABP4),
encoded byHABP4, is known to bind to FXR1 (fragile X mental retardation-related protein 1),
[22] suggesting thatHABP4 haploinsufficiency due to heterozygous deletion was involved in
the observed pathogenesis (i.e., mental retardation) observed in the Gorlin syndrome patient
from family F. This haploinsufficiency might have disrupted the interaction of HABP4 with
FXR1, although only one of the two affected family members clearly exhibited this phenotype.
In summary, we systematically screened individuals with familial Gorlin syndrome for caus-
ative genetic alterations using hybridization and PCR-based NGS, and found that various
PTCH1mutations, including large deletions, could explain the disease phenotypes. Because it
is advisable to examine the CNAs of candidate causative genes in point mutation-negative
cases, NGS methodology appears to be useful for improving the molecular diagnosis of Gorlin
syndrome through the simultaneous detection of both SNVs and CNAs in targeted genes/
regions.
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